Trademark/Service Mark Application, Principal Register
PTO- 1478
Approved for use through 02/28/2021. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Approved for use through 02/28/2021. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Serial Number:90495040
Filing Date:01/28/2021
To the Commissioner for Trademarks:
MARK: YUTRIVO (Standard Characters, see mark)
The literal element of the mark consists of YUTRIVO. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, AstraZeneca AB, a aktiebolag (ab) legally organized under the laws of Sweden, having an address of
Astraallén
Södertälje SE-15185
Sweden
302-886-6934(phone)
302-885-3762(fax)
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 005: Pharmaceutical preparations and substances
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
Based on Foreign Registration: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services, and will submit a copy of
European Union Trademark - EUTM registration number 018261258, and/or proof of renewal, registered 10/07/2020 with a renewal date of __________ and an expiration date of 06/25/2030, and translation
thereof, if appropriate.
The owner's/holder's proposed attorney information: Wm. Charles Saunders. Wm. Charles Saunders of AstraZeneca Pharmaceuticals LP, is a member of the XX bar, admitted to the bar in XXXX, bar
membership no. XXX, is located at
A2C
1800 Concord Pike
Wilmington, Delaware 19850-5437
United States
302-886-6934(phone)
302-885-3762(fax)
chuck.saunders@astrazeneca.com
The docket/reference number is 103873/US.
Wm. Charles Saunders submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any
U.S. Commonwealth or territory.
The applicant's current Correspondence Information:
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed,
and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).
Declaration
Declaration Signature
Signature: /wcs/ Date: 01/28/2021
Signatory's Name: Wm. Charles Saunders
Signatory's Position: Attorney of record, Pennsylvania Bar member
Signatory's Phone Number: 302-866-6934
Signature method: Sent to third party for signature
Payment Sale Number: 90495040
Payment Accounting Date: 01/28/2021
Serial Number: 90495040
Internet Transmission Date: Thu Jan 28 15:46:17 ET 2021
TEAS Stamp: USPTO/BAS-XXX.XX.XX.XXX-2021012815461710
2643-90495040-760d1da4f97dc31e4fae6ac3af
a4e37932c2ca4050ea279113e28fac5d3c3f491e
-DA-46169646-20210128144843490719